Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Compassionate Use of Opaganib For Patients with Severe COVID-19

Ramzi Kurd, Eli Ben-Chetrit, Hani Karameh, View ORCID ProfileMaskit Bar-Meir
doi: https://doi.org/10.1101/2020.06.20.20099010
Ramzi Kurd
1Internal medicine, Shaare-Zedek Medical Center, Jerusalem, IL
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli Ben-Chetrit
2Infectious diseases, Shaare-Zedek Medical Center, Jerusalem, IL
3The Faculty of Medicine, Hebrew University, Jerusalem, IL
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hani Karameh
1Internal medicine, Shaare-Zedek Medical Center, Jerusalem, IL
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maskit Bar-Meir
2Infectious diseases, Shaare-Zedek Medical Center, Jerusalem, IL
3The Faculty of Medicine, Hebrew University, Jerusalem, IL
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maskit Bar-Meir
  • For correspondence: mbarmeir@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Opaganib is a selective sphingosine-kinase (SK)-2 inhibitor with anti-inflammatory and anti-viral properties.

Methods We provided opaganib on a compassionate-use basis to patients with severe COVID-19. Patients who required oxygen support via high-flow nasal cannula (HFNC) were offered the treatment. For comparison, we used a control group with same-sex, same-severity patients.

Results Seven patients received at least one dose of opaganib since April 2, 2020. One patient, who received both hydroxychloroquine and azithromycin, developed diarrhea and all his medications were stopped. This was the only adverse effect possibly related to opaganib. A second patient was weaned of oxygen and discharged after receiving two doses of opaganib. Therefore, five patients were included in this analysis. Baseline characteristics were not significantly different between cases and controls. Patients treated with opaganib had significantly faster increase in lymphocyte count. All other clinical outcomes had a non-statistically significant trend in favor of the treatment group: median time to weaning from HFNC was 10 and 15 days in cases vs. controls (HR= 0.3, 95% CI: 0.07-1.7, p=0.2), time to ambient air was 13 vs.14.5 days (HR=0.4, 95% CI: 0.15-1.5), none of the cases required mechanical ventilation compared with 33% of controls.

Conclusion In this small cohort of severe COVID-19 patients, opaganib was safe and well tolerated with improvement in both clinical and laboratory parameters in all treated patients. The efficacy of opaganib for COVID-19 infection should be further tested in randomized placebo-controlled trials.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04435106

Funding Statement

RedHill Biopharma Ltd. provided the medication, but did not fund the study, nor was it involved in the conduct of treatment, follow-up, data collection or analyses.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was approved by the Shaare-Zedek Helsinki committee #0123-20-SZMC and by the Israeli ministry of health

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are not available at this point (pre-print)

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Compassionate Use of Opaganib For Patients with Severe COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Compassionate Use of Opaganib For Patients with Severe COVID-19
Ramzi Kurd, Eli Ben-Chetrit, Hani Karameh, Maskit Bar-Meir
medRxiv 2020.06.20.20099010; doi: https://doi.org/10.1101/2020.06.20.20099010
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Compassionate Use of Opaganib For Patients with Severe COVID-19
Ramzi Kurd, Eli Ben-Chetrit, Hani Karameh, Maskit Bar-Meir
medRxiv 2020.06.20.20099010; doi: https://doi.org/10.1101/2020.06.20.20099010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (553)
  • Anesthesia (135)
  • Cardiovascular Medicine (1761)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
  • Epidemiology (10803)
  • Forensic Medicine (8)
  • Gastroenterology (593)
  • Genetic and Genomic Medicine (2953)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1930)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (631)
  • Infectious Diseases (except HIV/AIDS) (12520)
  • Intensive Care and Critical Care Medicine (693)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2801)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1469)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (867)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2641)
  • Public and Global Health (5374)
  • Radiology and Imaging (1014)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (126)